Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Reform Bill Clears House; BIO Opposes Provision on Damages Awards

Executive Summary

A House patent reform provision on apportionment of damages in infringement suits is likely to be revised, despite House passage of the legislation Sept. 7 by a vote of 220-175

You may also be interested in...



House Focuses On Patent Reform, Other IP Issues With New Judiciary Subcommittee

Patent reform will be a priority for incoming House Judiciary Committee Chairman Lamar Smith, R.-Texas, who has created a subcommittee to spearhead development of legislation to protect Americans' intellectual assets.

House Focuses On Patent Reform, Other IP Issues With New Judiciary Subcommittee

Patent reform will be a priority for incoming House Judiciary Committee Chairman Lamar Smith, R.-Texas, who has created a subcommittee to spearhead development of legislation to protect Americans' intellectual assets.

Senators Oppose Patent Reform Provisions; GSK Also Urges Revisions To Bill

As patent reform legislation heads toward the Senate floor, members of the biotech and pharmaceutical industries are imploring legislators to alter key provisions. And a group of Senators is criticizing the bill's formulation for apportioning damage awards in infringement suits

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel